Among the treatment for ankylosing spondylitis (AS) currently available, there are several TNF-α inhibitors, targeting the proinflammatory cytokine TNF-α, released by a variety of cell types including NK cells. This evidence concerns the gene TNF and ankylosing spondylitis.